Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 21, 2022; 28(27): 3503-3513
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3503
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3503
Parameter | Training cohort (n = 296)1 | Validation cohort (n = 211)1 | P value |
Age (yr) | 42.47 ± 11.98 | 41.21 ± 11.36 | 0.167 |
Gender: Female/male (n) | 75/221 | 40/171 | 0.091 |
Drinking: Yes/no (n) | 127/169 | 101/110 | 0.268 |
Smoking: Yes/no (n) | 92/204 | 68/143 | 0.784 |
HbeAg: Negative/positive | 16/280 | 15/196 | 0.430 |
Fibrosis stage: F0/F1/F2/F3/F4 | 55/58/75/64/44 | 47/47/37/54/26 | 0.194 |
Activity grade: A0/A1/A2/A3/A4 | 16/92/113/69/6 | 15/72/69/52/3 | 0.446 |
WBC (× 109/L) | 5.89 ± 2.55 | 6.34 ± 4.32 | 0.150 |
NEUT × 109/L) | 3.55 ± 2.44 | 3.66 ± 2.61 | 0.611 |
LYMPH (× 109/L) | 1.72 ± 0.62 | 1.80 ± 0.63 | 0.063 |
PLT (× 109/L) | 171.61 ± 66.87 | 174.48 ± 61.62 | 0.636 |
Albumin (g/L) | 41.12 ± 19.09 | 39.94 ± 6.07 | 0.380 |
Globulin (g/L) | 29.67 ± 5.45 | 29.14 ± 5.80 | 0.298 |
TBIL (μmol/L) | 16.51 ± 8.44 | 16.73 ± 7.63 | 0.768 |
DBIL (μmol/L) | 6.91 ± 5.03 | 7.07 ± 4.33 | 0.699 |
ALT (U/L) | 73.31 ± 65.41 | 96.85 ± 83.62 | 0.002 |
AST (U/L) | 72.59 ± 63.29 | 77.44 ± 67.34 | 0.411 |
ALP (U/L) | 97.70 ± 41.98 | 104.32 ± 49.25 | 0.104 |
γ-GT (U/L) | 85.64 ± 69.68 | 97.98 ± 75.36 | 0.058 |
AGPR | 1.26 ± 0.84 | 1.32 ± 0.89 | 0.431 |
Parameter | Fibrosis (F0-1) (n = 113)1 | Fibrosis (F2-4) (n = 183)1 | P value |
Age (yr) | 45.15 ± 14.97 | 43.63 ± 13.32 | 0.363 |
Gender: Female/male (n) | 37/76 | 38/145 | 0.021 |
WBC (× 109/L) | 6.45 ± 3.02 | 5.55 ± 2.14 | 0.003 |
NEUT (× 109/L) | 4.14 ± 3.0 | 3.18 ± 1.95 | 0.001 |
LYMPH (× 109/L) | 1.67 ± 0.60 | 1.68 ± 0.63 | 0.828 |
PLT (× 109/L) | 206.0 ± 68.39 | 150.55 ± 56.49 | < 0.001 |
Albumin (g/L) | 41.26 ± 5.93 | 39.29 ± 5.66 | 0.005 |
Globulin (g/L) | 27.46 ± 4.46 | 31.04 ± 5.56 | < 0.001 |
TBIL (μmol/L) | 13.82 ± 7.06 | 17.12 ± 8.8 | < 0.001 |
DBIL (μmol/L) | 6.43 ± 3.72 | 7.81 ± 4.49 | < 0.001 |
ALT (U/L) | 65.01 ± 70.72 | 78.42 ± 66.62 | 0.101 |
AST (U/L) | 56.61 ± 55.11 | 82.45 ± 66.09 | 0.001 |
ALP (U/L) | 79.06 ± 34.16 | 109.2 ± 42.31 | < 0.001 |
γ-GT (U/L) | 51.84 ± 47.06 | 106.5 ± 73.21 | < 0.001 |
AGPR | 0.72 ± 0.49 | 1.61 ± 0.83 | < 0.001 |
Training cohort (n = 296) | Validation cohort (n = 211) | |||||||||||
F0-1 vs F2-4 | F0-2 vs F3-4 | F0-3 vs F4 | F0-1 vs F2-4 | F0-2 vs F3-4 | F0-3 vs F4 | |||||||
AGPR | ||||||||||||
AUROC (95%CI) | 0.83 (0.78-0.87) | 0.84 (0.79-0.88) | 0.87 (0.83-0.91) | 0.83 (0.77-0.88) | 0.83 (0.77-0.89) | 0.84 (0.78-0.89) | ||||||
Cut-off values | 0.87 | 1.20 | 1.40 | 0.87 | 1.20 | 1.40 | ||||||
Se/Sp (%) | 83.1/73.4 | 72.22/80.3 | 88.6/75.4 | 85.5/68.1 | 78.7/70.2 | 92.3/67.0 | ||||||
PPV/NPV (%) | 83.5/72.8 | 67.8/83.4 | 38.6/97.4 | 76.9/79.0 | 61.8/84.4 | 28.2/98.4 | ||||||
Positive/negative LR | 3.13/0.23 | 3.67/0.35 | 3.60/0.15 | 2.68/0.21 | 2.65/0.30 | 2.80/0.11 | ||||||
HR (95%CI) | 8.48 (5.22-14.33) | 7.56 (4.76-9.83) | 8.10 (5.11-11.63) | 8.02 (4.95-15.62) | 7.06 (4.51-12.35) | 5.06 (3.89-7.72) | ||||||
GPR | ||||||||||||
AUROC (95%CI) | 0.77 (0.72-0.82) | 0.81 (0.76-0.85) | 0.80 (0.75-0.84) | 0.80 (0.74-0.85) | 0.81 (0.74-0.87) | 0.78 (0.71-0.83) | ||||||
Cut-off values | 0.32 | 0.32 | 0.56 | 0.32 | 0.32 | 0.56 | ||||||
Se/Sp (%) | 73.7/70.8 | 76.8/54.8 | 79.5/65.9 | 86.3/67.0 | 91.2/56.5 | 75.0/62.3 | ||||||
PPV/NPV (%) | 80.4/62.5 | 49.4/80.5 | 28.9/94.9 | 76.5/79.7 | 56.2/91.4 | 26.5/86.9 | ||||||
Positive/negative LR | 2.53/0.37 | 1.70/0.42 | 2.33/0.31 | 2.62/0.20 | 2.10/0.15 | 1.95/0.41 | ||||||
HR (95%CI) | 6.53 (4.81-9.62) | 6.72 (3.96-9.63) | 6.47 (4.08-9.83) | 6.45 (3.58-11.61) | 7.30 (3.87-14.62) | 4.84 (3.28-7.95) | ||||||
APRI | ||||||||||||
AUROC (95%CI) | 0.72 (0.67-0.77) | 0.70 (0.64-0.75) | 0.76 (0.70-0.81) | 0.76 (0.70-0.82) | 0.74 (0.67-0.82) | 0.77 (0.70-0.83) | ||||||
Cut-off values | 0.5 | 1.5 | - | 1.0 | 2.0 | 0.5 | 1.5 | - | 1.0 | 2.0 | ||
Se/Sp (%) | 80.9/58.4 | 36.1/79.7 | - | 77.3/64.7 | 43.2/83.3 | 83.8/54.3 | 34.1/76.6 | - | 70.1/68.6 | 50.1/78.3 | ||
PPV/NPV (%) | 75.9/65.3 | 74.2/43.5 | - | 27.6/94.2 | 31.1/89.4 | 69.5/72.9 | 64.5/48.3 | - | 26.3/92.7 | 30.8/91.9 | ||
Positive/negative LR | 1.94/0.33 | 1.77/0.80 | - | 2.19/0.35 | 2.59/0.68 | 1.83/0.30 | 1.46/0.86 | - | 2.12/0.44 | 3.16/0.63 | ||
HR (95%CI) | 2.61 (1.85-3.67) | 1.85 (1.41-2.42) | 2.09 (1.63-2.55) | 1.59 (1.23-2.07) | 2.64 (1.76-4.32) | 2.13 (1.71-2.58) | ||||||
FIB-4 | ||||||||||||
AUROC (95%CI) | 0.74 (0.69-0.79) | 0.75 (0.69-0.80) | 0.80 (0.75-0.84) | 0.74 (0.67-0.80) | 0.79 (0.73-0.84) | 0.77 (0.71-0.83) | ||||||
Cut-off values | - | 1.45 | 3.25 | - | - | 1.45 | 3.25 | - | ||||
Se/Sp (%) | - | 87.9/47.3 | 42.6/87.2 | - | - | 77.5/58.1 | 37.5/93.1 | - | ||||
PPV/NPV (%) | - | 49.0/87.3 | 65.7/72.6 | - | - | 53.0/80.9 | 76.9/70.9 | - | ||||
Positive/negative LR | - | 1.67/0.25 | 3.34/0.66 | - | - | 1.85/0.39 | 5.46/0.67 | - | ||||
HR (95%CI) | 1.86 (1.52-2.53) | 1.94 (1.55-2.42) | 2.17 (1.77-2.56) | 1.98 (1.50-2.62) | 2.11 (1.63-2.74) | 1.87 (1.68-2.36) | ||||||
Comparison of AUROC | ||||||||||||
AGPR and GPR | P = 0.008 | P < 0.0001 | P = 0.0001 | P = 0.028 | P = 0.005 | P = 0.0008 | ||||||
AGPR and APRI | P < 0.0001 | P < 0.0001 | P = 0.0002 | P = 0.0001 | P = 0.0001 | P = 0.134 | ||||||
AGPR and FIB-4 | P = 0.0004 | P = 0.0005 | P = 0.022 | P = 0.007 | P = 0.174 | P = 0.100 | ||||||
GPR and APRI | P = 0.0007 | P = 0.0028 | P = 0.284 | P = 0.003 | P = 0.016 | P = 0.831 | ||||||
GPR and FIB-4 | P = 0.026 | P = 0.331 | P = 0.922 | P = 0.093 | P = 0.929 | P = 0.591 | ||||||
APRI and FIB-4 | P = 0.455 | P = 0.028 | P = 0.061 | P = 0.248 | P = 0.008 | P = 0.795 |
- Citation: Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China. World J Gastroenterol 2022; 28(27): 3503-3513
- URL: https://www.wjgnet.com/1007-9327/full/v28/i27/3503.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i27.3503